Birth control and diabetes are generally compatible. Long-acting reversible contraception (IUDs and implants) is first-line for most women with diabetes. Combined hormonal pills are safe in uncomplicated diabetes but should be avoided with vascular complications. Progestin-only methods are useful when combined methods aren’t appropriate. The WHO Medical Eligibility Criteria provides a structured framework, and glucose effects across all methods are usually minor.
Why Contraception Planning Matters With Diabetes
- Pre-conception A1C optimization (under 6.5%) substantially reduces congenital anomaly risk — planning matters
- Pregnancy spacing of 18 to 24 months improves outcomes
- Women with vascular complications may need time to optimize before pregnancy
- Unintended pregnancy in poorly controlled diabetes has high anomaly risk
- Reliable contraception is part of a comprehensive diabetes care plan for women of reproductive age
The WHO Medical Eligibility Criteria Framework
The WHO MEC categorizes contraceptive methods by safety for various medical conditions:
- Category 1: No restriction — method can be used in any circumstance
- Category 2: Advantages generally outweigh theoretical or proven risks
- Category 3: Theoretical or proven risks usually outweigh advantages — generally not recommended unless other methods unavailable or unacceptable
- Category 4: Unacceptable health risk — should not be used
Method-by-Method Eligibility With Diabetes
| Method | Uncomplicated Diabetes | With Vascular Complications |
|---|---|---|
| Copper IUD | Category 1 | Category 1 |
| Hormonal IUD (levonorgestrel) | Category 2 | Category 2 |
| Contraceptive implant (etonogestrel) | Category 2 | Category 2 |
| Progestin-only pill | Category 2 | Category 2 |
| Depo-Provera injection | Category 2 | Category 3 |
| Combined oral contraceptive | Category 2 | Category 3 or 4 |
| Contraceptive patch | Category 2 | Category 3 or 4 |
| Vaginal ring | Category 2 | Category 3 or 4 |
| Female sterilization | Accept (acute optimization may be needed) | Accept (acute optimization may be needed) |
| Male sterilization (partner) | Category 1 | Category 1 |
“Vascular complications” in this context include nephropathy, retinopathy, neuropathy, or other vascular disease, or diabetes duration of more than 20 years.
Long-Acting Reversible Contraception (LARC)
LARC methods — IUDs and implants — are first-line for most women with diabetes:
- Copper IUD (Paragard): Effective 10 to 12 years; no hormones; no glucose effect; heavier menses possible
- Hormonal IUD (Mirena, Kyleena, Liletta, Skyla): Effective 3 to 8 years depending on type; local levonorgestrel; reduces menstrual bleeding; minimal systemic effect
- Contraceptive implant (Nexplanon): Effective 3 years; small rod under skin of upper arm; etonogestrel; possible weight gain (modest)
Efficacy of LARC methods is over 99 percent — comparable to female sterilization but reversible.
Combined Hormonal Contraceptives
Combined methods contain both estrogen and progestin. The estrogen component drives most contraindications:
- Slight A1C nudge (1 to 3%) possible — rarely clinically significant
- Mild increase in insulin requirements in some women
- Cardiovascular risks magnified with smoking, hypertension, age over 35, vascular complications
- Generally safe in uncomplicated, young, non-smoking women with diabetes
- Options: pill, patch, vaginal ring — similar profiles
Progestin-Only Methods
Progestin-only methods avoid the estrogen-related risks of combined methods and are safer with vascular complications:
- Progestin-only pill (minipill): Requires strict daily timing; less effective than combined pills; minimal glucose effects
- Hormonal IUD: Local progestin, minimal systemic absorption; first-line LARC
- Contraceptive implant: Long-acting; first-line LARC
- Depo-Provera injection: Every 12 weeks; convenient; weight gain concern; possible mild glucose effects; bone density monitoring with long-term use
Depo-Provera Specifics
Depot medroxyprogesterone acetate (Depo-Provera) deserves separate discussion because it has the most distinct profile in women with diabetes:
- Weight gain — averages 5 to 10 pounds over the first year
- Possible modest decrease in insulin sensitivity
- Bone density loss (reversible after discontinuation) — concerning for younger women
- Long delay (often 6 to 12 months) in return of fertility after stopping
- WHO Category 2 in uncomplicated diabetes; Category 3 with vascular complications
- Useful when other methods aren’t feasible
Non-Hormonal Options
- Copper IUD: Most effective non-hormonal option; first-line LARC
- Condoms: Provide STI protection; lower efficacy if used alone (typical use ~13% failure rate)
- Diaphragm or cervical cap with spermicide: Less effective; rarely used today
- Fertility awareness methods: Variable efficacy; require strict tracking
- Sterilization: Permanent; tubal ligation or salpingectomy for women, vasectomy for partner
Emergency Contraception
- Levonorgestrel (Plan B): safe with diabetes; no contraindications
- Ulipristal acetate (Ella): safe with diabetes; more effective than levonorgestrel at later timing
- Copper IUD: most effective emergency contraception (over 99% effective); can be placed up to 5 days after unprotected intercourse
- No special diabetes-related considerations
Effects on Glucose Control
Most methods have minor effects on glucose patterns. Suggestions for monitoring after starting any method:
- Check glucose patterns over 4 to 8 weeks after starting
- Look for changes in insulin requirements (type 1) or A1C drift (type 2)
- If on a hormonal contraceptive and notice changes, discuss with both endocrinologist and gynecologist before changing methods
- Cycle-related glucose patterns may change with hormonal methods — sometimes for better (steadier)
Choosing a Method: Practical Framework
- Assess complications — retinopathy, nephropathy, neuropathy, hypertension, prior CVD
- Assess smoking and age
- Identify priorities — efficacy, reversibility, hormonal vs non-hormonal, daily action tolerance
- Discuss menstrual preferences — heavier (copper IUD) vs lighter (hormonal IUD)
- Consider future pregnancy timing — months vs years vs never
- Choose method aligned with priorities and eligibility
- Plan for placement, prescription, or referral
- Set follow-up to assess satisfaction and any glucose effects
Common Questions and Concerns
- “Does the IUD increase pelvic infection risk?”: No — modern evidence shows no increased risk of pelvic inflammatory disease beyond the first 20 days after placement
- “Can I get pregnant immediately after stopping?”: Yes, for most methods. Exception: Depo-Provera, where return of fertility can take 6 to 12 months
- “Do birth control pills interact with my diabetes medications?”: Minimal clinically significant interactions; some antibiotics affect combined pills but generally not diabetes medications
- “Should I stop birth control before pregnancy planning?”: Yes, typically 1 to 3 months before planned conception, depending on method
- “What about postpartum contraception?”: LARC methods can often be placed at hospital discharge; combined methods generally delayed until 6 weeks postpartum if breastfeeding (or used cautiously)
Postpartum Contraception After Diabetic Pregnancy
For women who’ve just had a baby with diabetes:
- LARC methods are first-line and can be placed at delivery or hospital discharge
- Progestin-only methods are compatible with breastfeeding from any timing
- Combined methods are generally delayed 6 weeks if breastfeeding (concern about milk supply)
- Spacing of 18 to 24 months supports optimal next-pregnancy outcomes
- Discuss before hospital discharge — this is a high-leverage moment
Related Reading
See our companion guides on preconception diabetes care, postpartum diabetes care, diabetes in women, and our menopause and diabetes guide.
The Bottom Line
Birth control and diabetes are generally compatible. The WHO Medical Eligibility Criteria provides a structured framework — most methods are Category 1 or 2 (safe) for uncomplicated diabetes. Long-acting reversible contraception (copper IUD, hormonal IUD, implant) is first-line for most women with diabetes — high efficacy, minimal glucose effects, no daily action. Combined hormonal pills are safe in uncomplicated young women with diabetes but should be avoided with vascular complications, smoking over age 35, or long-duration diabetes with multiple risk factors. Progestin-only methods are useful when combined methods aren’t appropriate. Depo-Provera has weight gain and bone density considerations. Glucose effects across methods are usually minor. Talk to your clinician about your specific complication profile, pregnancy plans, and preferences — reliable contraception is part of comprehensive diabetes care for women of reproductive age.
